EUVIMEDEUVIMED entdecken
Crossref

Apremilast

Aditya Kumar Bubna

Indian Journal of Drugs in Dermatology · 2016

DOI: 10.4103/2455-3972.196166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Indian Journal of Drugs in Dermatology, 2016. Verfasst von Aditya Kumar Bubna. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 46 Literaturangaben.

AbstractBibliografische AngabenZitieren

Abstract (Originalsprache)

Apremilast is an oral phosphodiesterase 4 inhibitor, now approved by the Food and Drug Administration in the management of psoriatic arthropathy (PsA). As biologic therapy is associated with significant amounts of adverse effects, newer treatment options with an efficacious outcome, sans the toxicity, is something all clinicians would implement readily in their therapeutic regimens. Apremilast is one such drug which has shown promise in the management of psoriasis, PsA, and a few other dermatologic disorders. This review will throw light on the dermatologic perspective regarding apremilast.

Zitieren

APA

Bubna, A. K. (2016). Apremilast. Indian Journal of Drugs in Dermatology. https://doi.org/10.4103/2455-3972.196166

Vancouver

Bubna AK. Apremilast. Indian Journal of Drugs in Dermatology. 2016. doi:10.4103/2455-3972.196166

BibTeX
@article{Bubna2016,
  author = {Bubna, Aditya Kumar},
  title = {Apremilast},
  journal = {Indian Journal of Drugs in Dermatology},
  year = {2016},
  doi = {10.4103/2455-3972.196166}
}
Kostenlos starten →